Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Del Barrio María, Sala Margarita, Gómez Judith, Horta Diana, Hernández-Guerra Manuel, Salcedo Magdalena, Goñi Silvia, Ríos-León Raquel, Herreros Ángela Martínez, González-Santiago Jesús M, Martínez Javier, Quintans Nerea C, Ampuero Javier, Antón María Dolores, Fernández-de la Varga Margarita, Escudero Desamparados, El Hajra Ismael, Cuenca Alarcón Francisca, Lorente Sara, Andrade Raúl J, Riveiro-Barciela Mar, Castello Inmaculada, Vergara Mercè, Quiñones Raisa, Arencibía Almeida Ana, Blanco Sampascual Sonia, Leal Carles, García-Retortillo Montserrat, Pérez-Medrano Indhira, Fernández-Bermejo Miguel, Morillas Rosa M, Gómez Elena, Tejedor-Tejada Javier, Roget Mercè, Rodríguez-Tajes Sergio, Alonso-Peña Marta, Álvarez-Cancelo Ana, Londoño María-Carlota, Díaz-González Álvaro
Аннотация
METHODS: A retrospective, multicenter cohort study including patients diagnosed with PBC enrolled in the Spanish ColHai registry.
RESULTS: A total of 469 patients with available data required for the study were included. Among them, 158 (33.7%) had SLD, and 124 (78.5%) met the diagnostic criteria for MASLD. Patients with PBC and SLD had lower baseline levels of alkaline phosphatase and higher liver stiffness at diagnosis. Regarding treatment response, no significant differences were observed across the different response criteria (Paris II, GLOBE, UK-PBC, deep response and complete normalization). Additionally, the presence of SLD was not associated with UDCA response at 1-year (Paris II: OR 1.04 [0.69-1.56]; GLOBE: OR 0.91 [0.58-1.44]; deep response: OR 1.08 [0.72-1.63]; complete normalization: OR 0.82 [0.52-1.30]). Baseline SLD was not associated with an increased risk of liver related-events in either the univariate analysis (HR 1.19, 95% CI 0.71-2.02) or in the different multivariate models evaluated. After inverse probability of treatment weighting (IPTW) using propensity scores, SLD still showed no significant impact on hepatic event development (HR 1.62; 95% CI 0.92-2.83).
CONCLUSION: Although SLD is frequently observed in PBC, it does not appear to adversely affect UDCA response or long-term hepatic outcomes.